| Referências: |
VILLAS BOAS, G.R., BOERNGEN DE LACERDA, R., PAES, M.M., GUBERT, P., ALMEIDA, W.L. DA C., RESCIA,
V.C., DE CARVALHO, P.M.G., DE CARVALHO, A.A.V., OESTERREICH, S.A., 2019. Molecular aspects of
depression: A review from neurobiology to treatment. Eur. J. Pharmacol. 851, 99–121.
https://doi.org/10.1016/j.ejphar.2019.02.024
BALDWIN, D. S.; AJEL, K. I.; GARNER, M. Pharmacological treatment of generalized anxiety disorder. In:
STEIN, M. B.; STECKLER, T. (Ed.). Behavioral Neurobiology of Anxiety and Its Treatment. Current Topics
in Behavioural Neurosciences. Heidelberg, Germany.: Springer-Verlag, 2010. p. 255–260.
CATHALA, A., DEVROYE, C., DRUTEL, G., REVEST, J.M., ARTIGAS, F., SPAMPINATO, U., 2019.
Serotonin2Breceptors in the rat dorsal raphe nucleus exert a GABA-mediated tonic inhibitory control on
serotonin neurons. Exp. Neurol. 311, 57–66. https://doi.org/10.1016/j.expneurol.2018.09.015
CRYAN, J. F.; SWEENEY, F. F. The age of anxiety: Role of animal models of anxiolytic action in drug
discovery. British Journal of Pharmacology, v. 164, n. 4, p. 1129–1161, 2011.
FAJEMIROYE, J. O. et al. Treatment of anxiety and depression: medicinal plants in
retrospect. Fundamental & Clinical Pharmacology, v. 30, n. 3, p. 198–215, 2016.
FERRARI, F., VILLA, R.F., 2016. The Neurobiology of Depression: an Integrated Overview from Biological
Theories to Clinical Evidence. Mol. Neurobiol. 54, 4847–4865.
HARRO, J. Animals, anxiety, and anxiety disorders: How to measure anxiety in rodents and
why. Behavioural Brain Research, n. 10, p. 1–13, 2017.
KRISHNAN, V., NESTLER, E.J., 2008. The molecular neurobiology of depression. Nature. 455, 894–
902. https://doi.org/10.1038/nature07455
MANJI, H.K., DREVETS, W.C., CHARNEY, D.S., 2001. Cellular Neurobiology of Depression. Nature 7, 541–
547.
DEVROYE, C., CATHALA, A., PIAZZA, P.V., SPAMPINATO, U., 2018. The central serotonin2Breceptor as a
new pharmacological target for the treatment of dopamine-related neuropsychiatric disorders:
Rationale and current status of research. Pharmacol. Ther. 181, 143–155.
https://doi.org/10.1016/j.pharmthera.2017.07.014
FASIPE, O.J., 2018. Neuropharmacological Classification of Antidepressant Agents Based on their
Mechanisms of Action. Arch. Med. Heal. Sci. 6, 81–94. https://doi.org/10.4103/amhs.amhs_7_18
GILHOTRA, N.; DHINGRA, D. Neurochemical modulation of anxiety disorders. International Journal of
Pharmacy and Pharmaceutical Sciences, v. 2, n. SUPPL. 1, p. 1–6, 2010.
HOFFMAN, E. J.; MATHEW, S. J. Anxiety Disorders: A Comprehensive Review of
Pharmacotherapies. Mount Sinai Journal of Medicine, v. 76, n. 2, p. 248–262, 2008.
NEUMEISTER, A.; DAHER, R. J.; CHARNEY, D. S. Anxiety disorders: noradrenergic
neurotransmission. Handbook Exp Pharmacol, v. 169, p. 205–223, 2005.
STRAWN, J. R.; GERACIOTI, T. D. Noradrenergic dysfunction and the psychopharmacology of
posttraumatic stress disorder. Depression and Anxiety, v. 25, n. 3, p. 260–271, 2008.
ARCHER J.; BOWER, P.; GILBODY, S.; LOVELL, K.; RICHARDS, D.; GASK, L.; et al. Collaborative care for
depression and anxiety problems. Cochrane Database of Systematic Reviews, v. 10, 2012.
BORSINI, F.; PODHORNA, J.; MARAZZITI, D. Do animal models of anxiety predict anxiolytic-like effects of
antidepressants? Psychopharmacology, v. 163, n. 2, p. 121–141, 2002.
VILLAS BOAS, G.R., STEFANELLO DA SILVEIRA, A.P., FEITOSA FARINELLI, B.C., LIMA CARDOSO, C.A.,
ARCE, E., OESTERREICH, S.A., 2018. The ethanolic extract obtained from Campomanesia pubescens
(D.C.) O.BERG fruits exerts anxiolytic and antidepressant effects on chronic mild stress model and on
anxiety models in Wistar rats: Behavioral evidences. Nutr. Neurosci. 0, 1–
11. https://doi.org/10.1080/1028415X.2018.146651 |
